Overview

To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.

Status:
RECRUITING

Trial end date:
2026-03-01

Target enrollment:

Participant gender:

Summary

Compared With Fosaprepitant dimeglumine for Injection and Palonosetron Hydrochloride Injection, to Evaluate the Efficacy and Safety of QLM2010 for Injection for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.

Phase:

PHASE3

Details

Lead Sponsor:

Qilu Pharmaceutical Co., Ltd.

Treatments:

fosaprepitant